Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development
Portfolio Pulse from
Coeptis Therapeutics announced that Phase 1 data on their COVID-19 treatment, DVX201, has been accepted for publication. The study shows the safety and feasibility of using allogeneic NK cells in high-risk COVID-19 patients, with no significant toxicities observed.
November 07, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Coeptis Therapeutics' Phase 1 study on DVX201, a COVID-19 treatment, shows promising safety results and has been accepted for publication. This could enhance the company's reputation and investor interest.
The acceptance of Phase 1 data for publication in a reputable journal suggests positive peer review, which can enhance Coeptis' credibility and attract investor interest. The safety results without significant toxicities are promising for future development.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100